Scynexis (SCYX) Change in Accured Expenses (2013 - 2026)
Scynexis' (SCYX) quarterly Change in Accured Expenses came in at $655000.0 in Q2 2026, up 528.1% on a YoY basis from $104282.0 in Q2 2025, and up 146.39% quarter-over-quarter from -$1.4 million in Q1 2026.
Analysis
Scynexis (SCYX) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Change in Accured Expenses for 14 consecutive years, with $655000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Accured Expenses rose 528.1% year-over-year to $655000.0; the trailing twelve-month figure through Jun 2026 stood at -$443000.0 (up 85.33% YoY), and the FY2025 full-year result was -$1.0 million, up 72.93% from the prior year.
- Change in Accured Expenses climbed to $655000.0 in Q2 2026 per SCYX's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $3.7 million in Q2 2022 and bottomed at -$5.8 million in Q1 2023.
- Historically, Change in Accured Expenses has averaged -$508777.8 across 5 years, with a median of -$71000.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses plunged 2125.97% in 2024, then jumped 2870.0% in 2025.
- Over 5 years, Change in Accured Expenses stood at -$70000.0 in 2022, then retreated by 10.0% to -$77000.0 in 2023, then slumped by 2125.97% to -$1.7 million in 2024, then soared by 100.99% to $17000.0 in 2025, then surged by 3752.94% to $655000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $655000.0, -$1.4 million, and $17000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 852.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 338.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 222.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 492.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -49.70 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -13.91 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 655,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 655,000.00 |
| Mar 31, 2026 | -1.41 Mn |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | 297,000.00 |
| Jun 30, 2025 | -153,000.00 |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | -1.71 Mn |
| Sep 30, 2024 | 10,000.00 |
| Jun 30, 2024 | 896,000.00 |
| Mar 31, 2024 | -2.89 Mn |
| Dec 31, 2023 | -77,000.00 |
| Sep 30, 2023 | -72,000.00 |
| Jun 30, 2023 | -68,000.00 |
| Mar 31, 2023 | -5.84 Mn |
| Dec 31, 2022 | -70,000.00 |
| Sep 30, 2022 | -1.70 Mn |
| Jun 30, 2022 | 3.74 Mn |
| Mar 31, 2022 | 383,000.00 |
| Dec 31, 2021 | -49,000.00 |
| Sep 30, 2021 | 3.78 Mn |